^BOSTON, March 12, 2024 (GLOBE NEWSWIRE) — Novotech (https://bit.ly/4bUg3sd),
the global clinical contract research organization (Clinical Research
Organization (CRO) with full service that works with biotech companies
collaborates to develop more advanced and novel
Accelerating therapeutics at every stage today has an industry-leading
Report on the clinical trial landscape for Duchenne muscular dystrophy (DMD)
(https://bit.ly/4bUg3sd) published.
The report covers new gene therapies, the funding landscape and a
SWOT analysis, which serves as a basis for strategic decision-making
drug development and ultimately the chances of successful and
to increase effective treatments against DMD. The Novotech analyst team
provides these expert reports free of charge on a monthly basis. These reports
provide up-to-date insights into global clinical trial activity and show
which regions have the highest study volumes and
what factors are behind these trends. They tackle the hurdles with which
Biotech companies face challenges in certain therapeutic areas, and
discuss future therapeutic paths and investment trends.
The report Duchenne Muscular Dystrophy – Global Clinical Trial Landscape
(https://bit.ly/4bUg3sd) (Duchenne Muscular Dystrophy – Global Clinical
Study landscape) examines the characteristics of DMD. It is the most common
Form of muscular dystrophy, it occurs more often in men, the lack of
Dystrophin protein (caused by a mutation) leads to a
Deterioration in muscle health, and the age at which DMD occurs
between 3 and 6 years. The disorder affects 1 in 5,000 males
Live births, with around 20,000 new diagnoses made worldwide every year
become. It is usually inherited from the mother, but occurs in 25% of cases
occurs spontaneously and without any family history.
The report also focuses on the epidemiology, the therapeutic
Challenges and evolving clinical trial data trends,
including treatments and financing, providing valuable insight
for healthcare professionals and researchers.
Treatment of the disease currently focuses on treating the
Symptoms and slowing of the disease progression while the current
Research focuses more on therapeutic approaches such as gene replacement, cell therapy and
Membrane stabilization concentrated.
The global prevalence of this complex genetic disorder varies
Region. Europe leads with the highest prevalence, followed by North America
APAC region and the rest of the world. Within Europe, countries such as Sweden,
Norway and Estonia with 16.7, 16.2 and 12.8 cases per 100,000 inhabitants respectively
Above-average diagnosis rates. In North America are Canada and
the USA at 10.6 and 10.2. In the APAC region, China leads with 10.3 cases per
100,000 inhabitants at the top.
Novotech’s research has shown that around 300 worldwide as of 2019
clinical trials of DMD have been initiated. North America is leading the way
Conducting studies (37%), followed by Asia Pacific (30%), Europe (24%)
and the rest of the world (9%).
The most important findings:
* Analysis of patient recruitment trends since 2019 in clinical
DMD studies in individual countries, with Europe compared to the USA and
The Asia-Pacific region consistently has shorter recruitment times and
has faster rates. This can be due to streamlined regulatory procedures,
greater patient awareness and more centralized
health systems.
* Especially in the USA there is a strong combination of public and
venture-focused funding for DMD, but also in the UK
and notable investments have been made in South Korea, with the
Most of the funding is focused on the preclinical phase.
* Current research into DMD is exploring gene and RNA therapies,
in particular techniques for membrane stabilization and interventions in
secondary cascades stand out as promising areas.
* There is a robust DMD drug development pipeline at 28
Drugs in preclinical stages, 14 in Phase I, 14 in Phase II and 9
in Phase III.
This comprehensive resource helps healthcare professionals, researchers and
Organizations to navigate the complex DMD landscape.
Download the report here (https://bit.ly/4bUg3sd)
About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-
cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD REPORT&utm_content=GBC)
Founded in 1997, Novotech is a global clinical
Full-service contract research organization (CRO) focused on
Collaboration with biotech companies focused on development
of advanced and novel therapeutics at every stage.
Recognized for its industry-leading contributions, Novotech has numerous
Received prestigious awards including the CRO Leadership Award
2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and
since 2006 the Asia-Pacific Contract Research Organization Company of the Year
Award.
The company offers a full range of services including
Laboratories, Phase I facilities, drug development consulting and
regulatory expertise, and has experience with over 5,000 clinical
Projects, including phase I to IV clinical trials and
Bioequivalence studies. With a presence in 34 locations and a dedicated
With a team of more than 3,000 professionals worldwide, Novotech is a trusted one
strategic end-to-end partner of choice.
For more information or to speak to an expert team member,
visit www.Novotech-CRO.com (http://www.novotech-cro.com/)
A photo accompanying this message is available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/50b76fdb-c279-
440f-8d82-f98d366c7d03
°